Rafarma Pharmaceuticals Company Top Management
RAFA Stock | USD 0.09 0 4.40% |
Rafarma Pharmaceuticals employs about 3 people. The company is managed by 3 executives with a total tenure of roughly 7 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Rafarma Pharmaceuticals' management performance can provide insight into the company performance.
Alexander Esq Insider Treasurer Sec |
Sergey JD Insider Chief Director |
Rafarma |
Rafarma Pharmaceuticals Management Team Effectiveness
Rafarma Pharmaceuticals' management efficiency ratios could be used to measure how well Rafarma Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.Rafarma Pharmaceuticals Workforce Comparison
Rafarma Pharmaceuticals is currently regarded as top stock in number of employees category among its peers. The total workforce of Drug Manufacturers—Specialty & Generic industry is at this time estimated at about 1,639. Rafarma Pharmaceuticals adds roughly 3.0 in number of employees claiming only tiny portion of equities under Drug Manufacturers—Specialty & Generic industry.
The company has Profit Margin (PM) of (0.88) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.81) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.81. Rafarma Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Rafarma Pharmaceuticals Price Series Summation is a cross summation of Rafarma Pharmaceuticals price series and its benchmark/peer.
Rafarma Pharmaceuticals Notable Stakeholders
A Rafarma Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rafarma Pharmaceuticals often face trade-offs trying to please all of them. Rafarma Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rafarma Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Alexander Esq | Treasurer Sec | Profile | |
Sergey JD | Chief Director | Profile | |
Anucha Phetpheng | Ex Operations | Profile |
About Rafarma Pharmaceuticals Management Performance
The success or failure of an entity such as Rafarma Pharmaceuticals often depends on how effective the management is. Rafarma Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rafarma management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rafarma management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Rafarma Pharmaceuticals, Inc., a multi-product pharmaceutical company, produces and sells drugs, generic antibiotics, and specialty pharmaceuticals in Russia. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. D. RAFARMA PHARMACEUTICALS operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange.
Please note, the presentation of Rafarma Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rafarma Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Rafarma Pharmaceuticals' management manipulating its earnings.
Rafarma Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Rafarma Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rafarma Pharmaceuticals within its industry.Rafarma Pharmaceuticals Manpower Efficiency
Return on Rafarma Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 4.9K | |
Net Loss Per Executive | 4.9K |
Complementary Tools for Rafarma Pink Sheet analysis
When running Rafarma Pharmaceuticals' price analysis, check to measure Rafarma Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rafarma Pharmaceuticals is operating at the current time. Most of Rafarma Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Rafarma Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rafarma Pharmaceuticals' price. Additionally, you may evaluate how the addition of Rafarma Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Money Managers Screen money managers from public funds and ETFs managed around the world |